These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 12866566

  • 1. Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer.
    Muc-Wierzgon M, Nowakowska-Zajdel E, Zubelewicz B, Wierzgon J, Kokot T, Klakla K, Szkilnik R, Wiczkowski A.
    J Exp Clin Cancer Res; 2003 Jun; 22(2):171-8. PubMed ID: 12866566
    [Abstract] [Full Text] [Related]

  • 2. Dynamics of diurnal changes in serum concentration of TNF-alpha soluble receptors in gastrointestinal cancer patients.
    Muc-Wierzgoń M, Baranowski MM, Madej K, Wierzgoń J, Kokot T, Brodziak A.
    J Biol Regul Homeost Agents; 2000 Jun; 14(3):204-8. PubMed ID: 11037054
    [Abstract] [Full Text] [Related]

  • 3. Dynamics of circadian fluctuations in serum concentration of cortisol and TNF-alpha soluble receptors in gastrointestinal cancer patients.
    Zubelewicz-Szkodzinska B, Muc-Wierzgon M, Wierzgon J, Brodziak A.
    Oncol Rep; 2001 Jun; 8(1):207-12. PubMed ID: 11115600
    [Abstract] [Full Text] [Related]

  • 4. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer.
    Barber MD, Fearon KC, Ross JA.
    Clin Sci (Lond); 1999 Jan; 96(1):83-7. PubMed ID: 9857110
    [Abstract] [Full Text] [Related]

  • 5. The estimation of endogenous tumor necrosis factor alpha and cortisol levels in serum in advanced neoplasm.
    Baranowski M, Muc-Wierzgon M, Madej K, Wierzgoń J, Zubelewicz B.
    J Exp Clin Cancer Res; 1999 Jun; 18(2):241-5. PubMed ID: 10464714
    [Abstract] [Full Text] [Related]

  • 6. Circadian rhythmometry of serum endogenous tumor necrosis factor-alpha in patients with colorectal cancer metastases.
    Muc-Wierzgoń M, Madej K, Baranowski M, Wierzgoń J.
    Eur Cytokine Netw; 1998 Jun; 9(2):193-6. PubMed ID: 9681396
    [Abstract] [Full Text] [Related]

  • 7. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
    Ocvirk J, Stabuc B, Rudolf Z, Galvani V, Curin-Serbec V.
    Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
    Perini P, Tiberio M, Sivieri S, Facchinetti A, Biasi G, Gallo P.
    Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
    [Abstract] [Full Text] [Related]

  • 9. Is there a correlation between tumor necrosis factor alpha and soluble p-55 receptor plasma levels in advanced gastrointestinal cancer patients?
    Muc-Wierzgoń M, Madej K, Baranowski M, Wierzgoń J.
    J Biol Regul Homeost Agents; 1996 Mar; 10(4):95-7. PubMed ID: 9604778
    [Abstract] [Full Text] [Related]

  • 10. [Measurement of the serum concentrations of tumor necrosis factor alpha and its soluble receptors in normal and pre-eclamptic pregnant patients].
    Núñez-González JR, Sanabria-Vera CJ, Romero-Adrián T.
    Invest Clin; 2001 Sep; 42(3):171-81. PubMed ID: 11552506
    [Abstract] [Full Text] [Related]

  • 11. Soluble cytokine receptors in renal vasculitis and lupus nephritis.
    Tesar V, Jirsa M, Zima T, Kalousová M, Bartunková J, Stejskalová A, Dostál C, Zabka J.
    Med Sci Monit; 2002 Jan; 8(1):BR24-9. PubMed ID: 11782670
    [Abstract] [Full Text] [Related]

  • 12. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP, Liljeström M, Laiho K, Tiitinen S, Kaarela K, Hurme M.
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [Abstract] [Full Text] [Related]

  • 13. Soluble tumor necrosis factor receptor II and soluble cell adhesion molecule 1 as markers of tumor necrosis factor-alpha release in preeclampsia.
    Visser W, Beckmann I, Knook MA, Wallenburg HC.
    Acta Obstet Gynecol Scand; 2002 Aug; 81(8):713-9. PubMed ID: 12174154
    [Abstract] [Full Text] [Related]

  • 14. Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients.
    Jabłońska E, Pietruska Z.
    Arch Immunol Ther Exp (Warsz); 1997 Aug; 45(5-6):449-53. PubMed ID: 9437501
    [Abstract] [Full Text] [Related]

  • 15. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock.
    Iglesias J, Marik PE, Levine JS, Norasept II Study Investigators.
    Am J Kidney Dis; 2003 Jan; 41(1):62-75. PubMed ID: 12500222
    [Abstract] [Full Text] [Related]

  • 16. Effects of an intravenous catheter on the local production of cytokines and soluble cytokine receptors in healthy men.
    Haack M, Reichenberg A, Kraus T, Schuld A, Yirmiya R, Pollmächer T.
    Cytokine; 2000 Jun; 12(6):694-8. PubMed ID: 10843747
    [Abstract] [Full Text] [Related]

  • 17. Further observations on the fetal inflammatory response syndrome: a potential homeostatic role for the soluble receptors of tumor necrosis factor alpha.
    Romero R, Maymon E, Pacora P, Gomez R, Mazor M, Yoon BH, Berry SM.
    Am J Obstet Gynecol; 2000 Nov; 183(5):1070-7. PubMed ID: 11084543
    [Abstract] [Full Text] [Related]

  • 18. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients.
    Jabłońska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jabłoński J.
    Arch Immunol Ther Exp (Warsz); 2001 Nov; 49(1):63-9. PubMed ID: 11266093
    [Abstract] [Full Text] [Related]

  • 19. Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients.
    Jablońska E, Kiluk M, Piotrowski L, Grabowska Z, Markiewicz W, Jablonski J.
    Eur Cytokine Netw; 1998 Jun; 9(2):155-9. PubMed ID: 9681391
    [Abstract] [Full Text] [Related]

  • 20. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
    Kaneyama K, Segami N, Sun W, Sato J, Fujimura K.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.